CN109966328B - Method for extracting ellagic acid and myrobalan acid from myrobalan and composition thereof - Google Patents
Method for extracting ellagic acid and myrobalan acid from myrobalan and composition thereof Download PDFInfo
- Publication number
- CN109966328B CN109966328B CN201910357486.7A CN201910357486A CN109966328B CN 109966328 B CN109966328 B CN 109966328B CN 201910357486 A CN201910357486 A CN 201910357486A CN 109966328 B CN109966328 B CN 109966328B
- Authority
- CN
- China
- Prior art keywords
- myrobalan
- parts
- acid
- extraction
- reflux
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 235000015489 Emblica officinalis Nutrition 0.000 title claims abstract description 98
- 235000011517 Terminalia chebula Nutrition 0.000 title claims abstract description 98
- 239000000203 mixture Substances 0.000 title claims abstract description 55
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 title claims abstract description 47
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 title claims abstract description 47
- 229920002079 Ellagic acid Polymers 0.000 title claims abstract description 47
- 235000004132 ellagic acid Nutrition 0.000 title claims abstract description 47
- 229960002852 ellagic acid Drugs 0.000 title claims abstract description 47
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 title claims abstract description 47
- 239000002253 acid Substances 0.000 title claims abstract description 44
- 238000000034 method Methods 0.000 title claims abstract description 17
- 244000277583 Terminalia catappa Species 0.000 title claims abstract 16
- 238000010992 reflux Methods 0.000 claims abstract description 73
- 238000000605 extraction Methods 0.000 claims abstract description 70
- 239000000284 extract Substances 0.000 claims abstract description 46
- 239000002904 solvent Substances 0.000 claims abstract description 40
- 239000007787 solid Substances 0.000 claims abstract description 24
- 238000002156 mixing Methods 0.000 claims abstract description 20
- 238000010298 pulverizing process Methods 0.000 claims abstract description 20
- 238000007873 sieving Methods 0.000 claims abstract description 20
- 206010061218 Inflammation Diseases 0.000 claims abstract description 18
- 230000004054 inflammatory process Effects 0.000 claims abstract description 18
- 230000004438 eyesight Effects 0.000 claims abstract description 13
- 239000012528 membrane Substances 0.000 claims abstract description 13
- 230000003467 diminishing effect Effects 0.000 claims abstract description 12
- 239000011347 resin Substances 0.000 claims abstract description 11
- 229920005989 resin Polymers 0.000 claims abstract description 11
- 238000001035 drying Methods 0.000 claims abstract description 8
- 238000001179 sorption measurement Methods 0.000 claims abstract description 6
- 238000001914 filtration Methods 0.000 claims abstract description 3
- 239000012982 microporous membrane Substances 0.000 claims abstract description 3
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims description 43
- 244000020518 Carthamus tinctorius Species 0.000 claims description 43
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 38
- 210000004369 blood Anatomy 0.000 claims description 27
- 239000008280 blood Substances 0.000 claims description 27
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 25
- 244000303040 Glycyrrhiza glabra Species 0.000 claims description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 25
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 24
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 21
- 238000002360 preparation method Methods 0.000 claims description 20
- 235000011477 liquorice Nutrition 0.000 claims description 19
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 18
- 240000001972 Gardenia jasminoides Species 0.000 claims description 18
- 230000036772 blood pressure Effects 0.000 claims description 15
- 230000001954 sterilising effect Effects 0.000 claims description 13
- 238000000926 separation method Methods 0.000 claims description 7
- PQLVXDKIJBQVDF-UHFFFAOYSA-N acetic acid;hydrate Chemical compound O.CC(O)=O PQLVXDKIJBQVDF-UHFFFAOYSA-N 0.000 claims description 6
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 6
- VLOVSFJPGNJHMU-UHFFFAOYSA-N ethanol;methanol;hydrate Chemical compound O.OC.CCO VLOVSFJPGNJHMU-UHFFFAOYSA-N 0.000 claims description 6
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 3
- 244000111489 Gardenia augusta Species 0.000 claims description 2
- 235000018958 Gardenia augusta Nutrition 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 43
- 239000003814 drug Substances 0.000 abstract description 22
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract description 19
- 206010020772 Hypertension Diseases 0.000 abstract description 15
- 230000008092 positive effect Effects 0.000 abstract description 3
- 244000191422 Terminalia bellirica Species 0.000 description 82
- 239000000243 solution Substances 0.000 description 28
- 230000000052 comparative effect Effects 0.000 description 19
- 235000013616 tea Nutrition 0.000 description 15
- 241000700159 Rattus Species 0.000 description 12
- 230000006870 function Effects 0.000 description 12
- 230000017531 blood circulation Effects 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 210000004204 blood vessel Anatomy 0.000 description 7
- 206010011224 Cough Diseases 0.000 description 6
- 235000005911 diet Nutrition 0.000 description 6
- 239000003480 eluent Substances 0.000 description 6
- 238000003304 gavage Methods 0.000 description 6
- 208000002193 Pain Diseases 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000037213 diet Effects 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- HGJXAVROWQLCTP-YABCKIEDSA-N Chebulagic acid Chemical compound O([C@H]1[C@H]2[C@H]3OC(=O)C4=CC(O)=C(O)C(O)=C4C4=C(O)C(O)=C(O)C=C4C(=O)OC[C@@H](O1)[C@H]3OC(=O)[C@@H](CC(O)=O)[C@@H]1[C@@H](C(OC=3C(O)=C(O)C=C(C1=3)C(=O)O2)=O)O)C(=O)C1=CC(O)=C(O)C(O)=C1 HGJXAVROWQLCTP-YABCKIEDSA-N 0.000 description 4
- 229920002052 Chebulagic acid Polymers 0.000 description 4
- 241000628997 Flos Species 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 239000003463 adsorbent Substances 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 230000001746 atrial effect Effects 0.000 description 4
- UGIVASYMZSZAMP-UHFFFAOYSA-N chebulagic acid Natural products OC1C2c3c(OC1=O)c(O)c(O)cc3C(=O)OC4C(OC(=O)c5cc(O)c(O)c(O)c5)OC6COC(=O)c7cc(O)c(O)c(O)c7c8c(O)c(O)c(O)cc8C(=O)OC4C6OC(=O)C2(O)C(=O)O UGIVASYMZSZAMP-UHFFFAOYSA-N 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 210000001105 femoral artery Anatomy 0.000 description 4
- 208000010125 myocardial infarction Diseases 0.000 description 4
- 208000031225 myocardial ischemia Diseases 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 210000000582 semen Anatomy 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 206010048962 Brain oedema Diseases 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 3
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 3
- 235000017443 Hedysarum boreale Nutrition 0.000 description 3
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 3
- 206010062717 Increased upper airway secretion Diseases 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 241001122767 Theaceae Species 0.000 description 3
- 206010047141 Vasodilatation Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 208000006752 brain edema Diseases 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 3
- 210000000038 chest Anatomy 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 230000000302 ischemic effect Effects 0.000 description 3
- 229940010454 licorice Drugs 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 230000002107 myocardial effect Effects 0.000 description 3
- 208000026435 phlegm Diseases 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 229920001864 tannin Polymers 0.000 description 3
- 235000018553 tannin Nutrition 0.000 description 3
- 239000001648 tannin Substances 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 230000024883 vasodilation Effects 0.000 description 3
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- 206010001497 Agitation Diseases 0.000 description 2
- 241001474374 Blennius Species 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- 241000005787 Cistanche Species 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 241001289529 Fallopia multiflora Species 0.000 description 2
- 241000202807 Glycyrrhiza Species 0.000 description 2
- 240000006509 Gynostemma pentaphyllum Species 0.000 description 2
- 235000002956 Gynostemma pentaphyllum Nutrition 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- 229930194248 Licoflavone Natural products 0.000 description 2
- MEHHCBRCXIDGKZ-UHFFFAOYSA-N Licoflavone C Natural products CC(C)=CCC1=C(O)C=C(O)C(C(C=2)=O)=C1OC=2C1=CC=C(O)C=C1 MEHHCBRCXIDGKZ-UHFFFAOYSA-N 0.000 description 2
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 2
- 241000112528 Ligusticum striatum Species 0.000 description 2
- 235000003181 Panax pseudoginseng Nutrition 0.000 description 2
- 244000131316 Panax pseudoginseng Species 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- 241001080798 Polygala tenuifolia Species 0.000 description 2
- 244000046146 Pueraria lobata Species 0.000 description 2
- 235000010575 Pueraria lobata Nutrition 0.000 description 2
- 241000304195 Salvia miltiorrhiza Species 0.000 description 2
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 description 2
- 235000017089 Scutellaria baicalensis Nutrition 0.000 description 2
- 240000004534 Scutellaria baicalensis Species 0.000 description 2
- 235000009818 Trichosanthes kirilowii Nutrition 0.000 description 2
- 240000006023 Trichosanthes kirilowii Species 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 230000003266 anti-allergic effect Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 2
- 239000001685 glycyrrhizic acid Substances 0.000 description 2
- 229960004949 glycyrrhizic acid Drugs 0.000 description 2
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 2
- 235000019410 glycyrrhizin Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 235000009200 high fat diet Nutrition 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- LTINPJMVDKPJJI-UHFFFAOYSA-N iodinated glycerol Chemical compound CC(I)C1OCC(CO)O1 LTINPJMVDKPJJI-UHFFFAOYSA-N 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 244000112814 pipewort Species 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- 230000008359 toxicosis Effects 0.000 description 2
- 230000002936 tranquilizing effect Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 229940126673 western medicines Drugs 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- JLTCWSBVQSZVLT-CDIPANDDSA-N (2s)-n-[(2s)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[(4r,7s,10s,13s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosan Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](N)CSSC1.C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 JLTCWSBVQSZVLT-CDIPANDDSA-N 0.000 description 1
- MUKYLHIZBOASDM-UHFFFAOYSA-N 2-[carbamimidoyl(methyl)amino]acetic acid 2,3,4,5,6-pentahydroxyhexanoic acid Chemical compound NC(=N)N(C)CC(O)=O.OCC(O)C(O)C(O)C(O)C(O)=O MUKYLHIZBOASDM-UHFFFAOYSA-N 0.000 description 1
- 235000020926 24-h fasting Nutrition 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 241000427159 Achyranthes Species 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 244000061520 Angelica archangelica Species 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 241000132012 Atractylodes Species 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 235000003717 Boswellia sacra Nutrition 0.000 description 1
- 235000012035 Boswellia serrata Nutrition 0.000 description 1
- 240000007551 Boswellia serrata Species 0.000 description 1
- 241001415440 Bufo gargarizans Species 0.000 description 1
- 241000219357 Cactaceae Species 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 244000183685 Citrus aurantium Species 0.000 description 1
- 235000007716 Citrus aurantium Nutrition 0.000 description 1
- 240000007311 Commiphora myrrha Species 0.000 description 1
- 235000006965 Commiphora myrrha Nutrition 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- SEBIKDIMAPSUBY-ARYZWOCPSA-N Crocin Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)C(C)=CC=CC(C)=C\C=C\C=C(/C)\C=C\C=C(C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1)O)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SEBIKDIMAPSUBY-ARYZWOCPSA-N 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 206010013952 Dysphonia Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241001632410 Eleutherococcus senticosus Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000208688 Eucommia Species 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010016952 Food poisoning Diseases 0.000 description 1
- 208000019331 Foodborne disease Diseases 0.000 description 1
- 239000004863 Frankincense Substances 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 1
- 240000008397 Ganoderma lucidum Species 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 235000001287 Guettarda speciosa Nutrition 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 208000010473 Hoarseness Diseases 0.000 description 1
- 206010020601 Hyperchlorhydria Diseases 0.000 description 1
- 206010010164 Hypertension complications Diseases 0.000 description 1
- 201000001431 Hyperuricemia Diseases 0.000 description 1
- 208000019025 Hypokalemia Diseases 0.000 description 1
- 206010022562 Intermittent claudication Diseases 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- 206010024453 Ligament sprain Diseases 0.000 description 1
- FURUXTVZLHCCNA-UHFFFAOYSA-N Liquiritigenin Natural products C1=CC(O)=CC=C1C1OC2=CC(O)=CC=C2C(=O)C1 FURUXTVZLHCCNA-UHFFFAOYSA-N 0.000 description 1
- 241000699684 Meriones unguiculatus Species 0.000 description 1
- 235000007265 Myrrhis odorata Nutrition 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 244000170916 Paeonia officinalis Species 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 240000007711 Peperomia pellucida Species 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 244000274050 Platycodon grandiflorum Species 0.000 description 1
- 235000006753 Platycodon grandiflorum Nutrition 0.000 description 1
- 235000008599 Poria cocos Nutrition 0.000 description 1
- 244000197580 Poria cocos Species 0.000 description 1
- 102000005320 Posterior Pituitary Hormones Human genes 0.000 description 1
- 108010070873 Posterior Pituitary Hormones Proteins 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 206010038084 Rectocele Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000004078 Snake Bites Diseases 0.000 description 1
- 208000010040 Sprains and Strains Diseases 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 241000001522 Terminalia chebula Species 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 241001521901 Tribulus lanuginosus Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 241000028204 Vincetoxicum atratum Species 0.000 description 1
- 241000159213 Zygophyllaceae Species 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 102000004305 alpha Adrenergic Receptors Human genes 0.000 description 1
- 108090000861 alpha Adrenergic Receptors Proteins 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000001458 anti-acid effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 230000036471 bradycardia Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 230000003177 cardiotonic effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 208000024980 claudication Diseases 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000008828 contractile function Effects 0.000 description 1
- 230000009519 contusion Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 229940124567 diuretic antihypertensive agent Drugs 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000037024 effective refractory period Effects 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 208000023062 epigastric abdominal pain Diseases 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 239000009627 gardenia yellow Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- JBQATDIMBVLPRB-UHFFFAOYSA-N isoliquiritigenin Natural products OC1=CC(O)=CC=C1C1OC2=CC(O)=CC=C2C(=O)C1 JBQATDIMBVLPRB-UHFFFAOYSA-N 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000010699 lard oil Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- FURUXTVZLHCCNA-AWEZNQCLSA-N liquiritigenin Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=CC(O)=CC=C2C(=O)C1 FURUXTVZLHCCNA-AWEZNQCLSA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 244000138993 panchioli Species 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 208000024896 potassium deficiency disease Diseases 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- KINGXFAMZNIVNL-SXQDSXCISA-N safflor yellow A Natural products OC[C@@H]1O[C@H]2[C@H](OC3=C2C(=O)C(=C(O)C=Cc4ccc(O)cc4)C(=O)[C@]3(O)[C@@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)[C@@H](O)[C@H]1O KINGXFAMZNIVNL-SXQDSXCISA-N 0.000 description 1
- 235000009165 saligot Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- GSZUGBAEBARHAW-UHFFFAOYSA-N sophoraflavone B Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C=2OC3=CC(O)=CC=C3C(=O)C=2)C=C1 GSZUGBAEBARHAW-UHFFFAOYSA-N 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 230000003639 vasoconstrictive effect Effects 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
- A23F3/34—Tea substitutes, e.g. matè; Extracts or infusions thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/744—Gardenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to the field of traditional Chinese medicine extracts, and in particular relates to an extraction method of ellagic acid and myrobalamin acid in myrobalan and a composition thereof. The method comprises the following steps: pretreating, pulverizing and sieving myrobalan; extracting pulverized fructus Chebulae under reflux, and filtering with microporous membrane to obtain solid A and extractive solution A; carrying out reflux extraction on the solid A, and then passing through a microporous filter membrane to obtain a solid B and an extracting solution B; mixing the extract A and the extract B, concentrating, passing through macroporous adsorption resin, eluting with solvent, crystallizing, and drying to obtain ellagic acid and myrobalan acid in fructus Chebulae. The extraction method can be used for pertinently extracting the ellagic acid and the myrobalan acid in the myrobalan, and the content purity of the ellagic acid and the myrobalan acid is high. The invention also provides a product with positive effects on treating hypertension and hyperlipidemia, and also has the effects of diminishing inflammation and improving eyesight.
Description
Technical Field
The invention relates to the field of traditional Chinese medicine extracts, and in particular relates to an extraction method of ellagic acid and myrobalamin acid in myrobalan and a composition thereof.
Background
With the rapid development of economy, the dietary structure and habits of people are greatly changed, and many people have excessive energy intake while having gulosity meals, so that the so-called 'rich diseases' represented by hypertension and hyperlipidemia are followed. Hypertension and hyperlipidemia are the sources of many diseases, and with high-fat and high-salt diet and unreasonable diet habits, human metabolism is disordered. Hyperlipidemia can cause blood lipid increase, and is a risk factor for stroke, coronary heart disease, myocardial infarction and sudden death. In addition, hyperlipidemia is also an important risk factor for the promotion of hyperlipidemia, impaired glucose tolerance, and diabetes. Hyperlipidemia can also lead to fatty liver, liver cirrhosis, cholelithiasis, pancreatitis, fundus hemorrhage, blindness, peripheral vascular disease, claudication, and hyperuricemia. Therefore, the harm of hyperlipidemia must be paid high attention to, and active prevention and conditioning are required. High salt easily induces hypertension, the disease generally has slow onset, the early stage of a patient often has no symptoms, or only has symptoms such as dizziness, headache, palpitation, tinnitus and the like, the disease is seemingly an independent disease, and is actually an important risk factor for causing heart, cerebral vessels and kidney diseases, and if the treatment is improper, the disease becomes serious common hypertension complications such as cerebral apoplexy, myocardial infarction, renal failure and the like.
Western medicines are mainly used for treating three highs, and hypertension and hyperlipidemia can be effectively controlled. However, western medicines often cause some adverse reactions while being effectively adjusted, such as: the diuretic antihypertensive medicine has the main side effects of hypokalemia and hyperlipidemia (blood fat, blood sugar and blood uric acid). Drug side effects have become one of the important problems affecting long-term sustained treatment and quality of life and must be properly recognized and properly managed.
In recent years, the research on myrobalan in the field of traditional Chinese medicine has further progressed, and the extracted effective substances ellagic acid and myrobalan acid have good effects of reducing three highs, diminishing inflammation, improving eyesight and strengthening heart. Modern pharmacological research shows that the myrobalan has various pharmacological effects of neuroprotection, oxidation resistance, cardiotonic, antibacterial, anti-tumor, hypertension, hyperglycemia, hyperlipidemia and the like. The main chemical components include tannin, triterpenes, flavonoids, etc.
The invention patent application CN101433563A discloses an effective component of myrobalan, the preparation process comprises the following steps: step 1: extracting the myrobalan by using a mixture of ethyl acetate and ethanol as a solvent, and performing step 2: extracting the medicine residues with ethanol to obtain an extracting solution, and performing step 3: the eluent is obtained from the extract through chromatographic column chromatography. And 4, step 4: and (3) using the eluent obtained by the preparation of liquid chromatography gradient elution, wherein the mobile phase is water and acetonitrile, and collecting the eluent for 48.0-52.0 minutes to obtain the effective component. The invention also discloses a preparation method thereof, a pharmaceutically acceptable preparation and application thereof in preparing antitumor drugs. As can be seen from figure 1, the number of the extracted components is at least 6, and the types of the extracted components are complex, so that the effective components cannot exert the drug effect better.
The invention patent application CN108338996A discloses a method for preparing tannin type active ingredients in myrobalan, which comprises the following steps: ultrasonically extracting fructus Chebulae powder with anhydrous ethanol, and concentrating the extractive solution under reduced pressure to obtain extract; dissolving the extract with appropriate amount of water, separating with macroporous adsorbent resin column chromatography, gradient eluting with pure water and ethanol with volume fractions of 20%, 40%, 60%, 80%, 90% and 95%, collecting 90% ethanol eluate, separating with silica gel column chromatography, eluting with chloroform-methanol with volume ratios of 65:1, 55:1, 45:1, 35:1, 25:1 and 10:1, collecting 25:1 eluate, and concentrating. The preparation method can effectively obtain tannin type effective components in fructus Chebulae, has antioxidant, antibacterial and antitumor activities, and can be used as effective component of fructus Chebulae for medicine preparation. But the components obtained according to the technical scheme have lower content and lower purity.
The research shows that the myrobalamin acid and the ellagic acid extracted from the myrobalan are compatible with other traditional Chinese medicine raw materials for use, and have great promotion effects on treating hypertension and hyperlipidemia, diminishing inflammation and improving eyesight
The invention patent application CN107308290A discloses a health-care granular tea for reducing blood pressure, blood fat and blood sugar, which comprises the following components in parts by weight: 3-15 parts of angelica, 3-15 parts of radix rehmanniae, 4-20 parts of peach kernel, 3-15 parts of safflower, 2-10 parts of bitter orange, 2-10 parts of red peony root, 3-15 parts of radix bupleuri, 2-10 parts of liquorice, 2-10 parts of platycodon grandiflorum, 2-10 parts of ligusticum wallichii, 3-15 parts of achyranthes root, 3-15 parts of frankincense, 3-15 parts of myrrh, 4-20 parts of dried orange peel, 4-20 parts of rhizoma pinellinae praeparata and 8-22 parts of poria cocos. The health-care granular tea prepared according to the proportion has the advantages of definite curative effect of reducing blood pressure, reducing blood fat and reducing blood sugar, is convenient to take, has no toxic or side effect, improves the functions of a human body by promoting blood circulation to remove blood stasis, reducing phlegm and dredging collaterals, conditioning deficiency of five internal organs and regulating the internal and external functions, and is suitable for the health-care prevention needs and the disease treatment and rehabilitation needs of common people. However, tests show that the traditional Chinese medicine composition has poor curative effect on reducing blood pressure and blood fat and has no obvious effect.
The invention patent application CN108619108A discloses an application of Shenqixinshu capsule and a preparation method thereof, belonging to the technical field of traditional Chinese medicines. The Shenqixinshu capsule comprises the following raw materials in parts by weight: 60-120 parts of pseudo-ginseng, 60-120 parts of salvia miltiorrhiza, 100 parts of ganoderma lucidum, 60-120 parts of kudzu, 50-100 parts of safflower, 60-120 parts of ligusticum wallichii, 90-180 parts of dalbergia wood, 100 parts of eucommia bark, 100 parts of cynanchum atratum, 300 parts of cactus and 600 parts of liquorice. The Shenqixin Shugan capsule has the advantages of natural effect, simple process and low cost. The preparation method simulates ethnic group usage and is decocted with water, and in the production process, the pseudo-ginseng, the salvia miltiorrhiza and the radix puerariae are used as the medicine by being crushed into fine powder, so that the effective components are fully reserved, 60% of forming auxiliary materials are replaced, and the preparation method has good functions of reducing blood pressure, blood fat, blood sugar and blood platelet aggregation, and has a wide application range. However, the traditional Chinese medicine has single effect and does not have good effects of clearing heat, diminishing inflammation and improving eyesight.
The invention patent application CN102599595A discloses a health drink with the function of reducing blood fat, which comprises the following components: the traditional Chinese medicine additive comprises 10-20 wt% of traditional Chinese medicine additive and deionized water, wherein the traditional Chinese medicine additive comprises the following components of radix sophorae flavescentis, root of kudzu vine, acanthopanax senticosus, polygonum multiflorum, caltrop, gynostemma pentaphylla, rhizoma anemarrhenae, safflower, semen cassiae, scutellaria baicalensis, trichosanthes kirilowii maxim, caulis spatholobi, polygala tenuifolia, bighead atractylodes rhizome, seaweed, cape jasmine fruit, pipewort, liquorice, cistanche and semen cuscutae. The health-care beverage containing the traditional Chinese medicine components and the preparation method thereof adopt the ultra-high pressure technology under the specific conditions, the ultra-high pressure technology under the specific conditions can extract the effective components in the traditional Chinese medicine to the maximum extent, the extraction efficiency is improved, the health-care beverage has the advantages of high efficiency, rapidness, convenience, automation and the like, the obtained health-care beverage has a remarkable effect on reducing blood fat, and the hyperlipidemia is well prevented and treated. The application also has the defect of single effect, can only treat the hyperlipidemia, and has no positive effects on hypertension, inflammation diminishing, sterilization and eyesight improvement.
At present, people who are troubled by hypertension and hyperlipidemia have poor resistance, certain inflammation exists in the body, and the body inflammation is treated while the hypertension and the hyperlipidemia are treated. There is no method for effectively extracting ellagic acid and myrobalan acid from myrobalan, which can be used for pertinently extracting the ellagic acid and the myrobalan acid from the myrobalan, and the content purity of the ellagic acid and the myrobalan acid is high. The prior art also has no product which has positive effects on treating hypertension and hyperlipidemia and has the effects of diminishing inflammation and improving eyesight.
Disclosure of Invention
In order to solve the problems of complex purification components, low purity and the like in the prior art, the invention provides a method for extracting ellagic acid and myrobalan acid from myrobalan, which comprises the following steps:
(1) pretreatment: pulverizing fructus Chebulae, and sieving;
(2) extraction 1: extracting pulverized fructus Chebulae under reflux, and filtering with microporous membrane to obtain solid A and extractive solution A;
(3) and (3) extraction 2: carrying out reflux extraction on the solid A, and then passing through a microporous filter membrane to obtain a solid B and an extracting solution B;
(4) separation: mixing the extract A and the extract B, concentrating, passing through macroporous adsorption resin, eluting with solvent, crystallizing, and drying to obtain ellagic acid and myrobalan acid in fructus Chebulae.
Further, in the step (1), the powder is crushed and sieved by 200 meshes and 300 meshes.
Further, in the step (2), the solvent used for reflux extraction is methanol-ethanol-water solution; the solvent comprises the following components in parts by weight: myrobalan (8-12): 1, methanol: ethanol: water 5: (5-10): 1.
further, in the step (2), the reflux extraction conditions are as follows: the reflux temperature is 45-65 ℃; the reflux time is 1-3 h.
Further, in the step (3), the solvent used for reflux extraction is acetic acid-water solution; the solvent comprises the following components in parts by weight: myrobalan ═ 5-10: 1, acetic acid: water ═ 2-5: 1.
further, in the step (3), the reflux extraction conditions are as follows: the reflux temperature is 65-80 ℃; the reflux time is 1-3 h.
Further, in the step (4), the macroporous absorption resin is one of HPD-100, D-101 or SD-300.
Further, in the step (4), the solvent is one of ethanol-water or methanol-water; eluent comprises the following components in parts by weight: (extract a + extract B) ═ 5-11: 1.
further, in the step (4), the weight parts of ethanol: water ═ 5-8: 1.
further, in the step (4), the weight ratio of methanol: water ═ 2-6: 1.
in order to solve the problems that the product in the prior art has single effect and can not treat hypertension, hyperlipidemia and inflammation caused by hypertension and hyperlipidemia at the same time, the invention provides a composition for reducing blood pressure and blood fat, diminishing inflammation and improving eyesight, which comprises the following components: carthami flos, fructus Chebulae, fructus Gardeniae, Glycyrrhrizae radix, and ellagic acid and chebulagic acid extract of above fructus Chebulae.
Further, the coating comprises the following components in parts by weight: 5-15 parts of safflower, 5-15 parts of myrobalan, 1-10 parts of gardenia, 1-8 parts of liquorice and 0.01-0.03 part of ellagic acid and myrobalan acid in the myrobalan.
Furthermore, the coating comprises the following components in parts by weight: 9 parts of safflower, 10 parts of myrobalan, 5 parts of gardenia, 3 parts of liquorice, and 0.01 part of ellagic acid and myrobalan acid in the myrobalan.
Furthermore, the coating comprises the following components in parts by weight: 5 parts of safflower, 5 parts of myrobalan, 2 parts of gardenia, 5 parts of liquorice, and 0.02 part of ellagic acid and myrobalan acid in the myrobalan.
Further, the safflower comprises the following components in parts by weight: 1, myrobalan: and 1 is selected from gardenia (1-3).
Further, the safflower comprises the following components in parts by weight: 1, myrobalan: gardenia fruit (1.5-2.5): 1.
Further, the safflower: licorice root 3:1, myrobalan: 2:1 of gardenia.
Further, the safflower: 1:1 ratio of liquorice, myrobalan: gardenia 2.5: 1.
The invention also provides a preparation method of the composition, which comprises the following steps: mixing all the components, pulverizing, sieving, and sterilizing to obtain the composition.
Further pulverizing and sieving with 60-80 mesh sieve.
Further, the powder was ground and sieved through a 70 mesh sieve.
Further, the method comprises the following steps: mixing Carthami flos 5-15 parts, fructus Chebulae 5-15 parts, fructus Gardeniae 1-10 parts, Glycyrrhrizae radix 1-8 parts, ellagic acid in fructus Chebulae and 0.01-0.03 part of myrobalic acid, pulverizing, sieving with 60-80 mesh sieve, and sterilizing to obtain the composition.
Further, the method comprises the following steps: mixing Carthami flos 9 parts, fructus Chebulae 10 parts, fructus Gardeniae 5 parts, Glycyrrhrizae radix 3 parts, ellagic acid in fructus Chebulae and 0.01 part of chebulagic acid, pulverizing, sieving with 70 mesh sieve, and sterilizing to obtain the composition.
Further, the method comprises the following steps: mixing 5 parts of safflower, 5 parts of myrobalan, 2 parts of gardenia, 5 parts of liquorice, and 0.02 part of ellagic acid and myrobalan acid in the myrobalan, crushing, sieving with a 70-mesh sieve, and sterilizing to obtain the composition.
The invention also provides an extract obtained by the extraction method, the composition or the application of the composition obtained by the preparation method in the preparation of health-care tea.
Theoretical basis:
safflower, also called as safflower and thorn safflower, is of Compositae and safflower, has the functions of promoting blood circulation and stimulating the menstrual flow, removing blood stasis and relieving pain, and is helpful for treating amenorrhea, dysmenorrhea, lochiorrhea, thoracic obstruction and pain, stasis and abdominal pain, stabbing pain in chest and hypochondrium, traumatic injury and sore and ulcer swelling and pain. Has the effects of promoting blood circulation, removing blood stasis, eliminating dampness and swelling, and can be used for preventing pregnant women from abortion.
The efficacy of safflower is:
1. inhibition of cardiac action: the small dosage of the safflower decoction can cause the in vitro heart of the toad and the heart of the rabbit in vivo to be slightly excited, so that the heartbeat is powerful and the amplitude is increased; the large dosage can inhibit heart, slow heart rate, weaken myocardial contractility, and reduce cardiac output.
2. Experimental studies on coronary blood flow indicate that: the water extract and water-soluble mixture of Carthami flos, HONGHUAHUASU, have the effects of increasing coronary blood flow and myocardial nutritional blood flow; the functions of expanding coronary artery and increasing coronary blood flow of the ethanol extract of safflower are not obvious or have no influence.
3. Experimental studies on experimental myocardial ischemia and myocardial infarction showed that: safflower and its preparation have different degrees of antagonistic action on animal models of rabbit, rat, dog, etc. causing experimental myocardial ischemia or myocardial infarction. The safflower can obviously protect the acute myocardial ischemia of rats or rabbits caused by the pituitrin; the method can obviously reduce the degree of acute myocardial ischemia of the anesthetized dog caused by repeated and transient blockage of coronary artery blood flow, reduce the range and slow the heart rate, protect the edge of an acute myocardial infarction area, narrow the infarction range and reduce the elevation amplitude of the electrocardiogram ST section at the edge area, thereby improving the supply and demand relationship of ischemic myocardial oxygen.
4. The research on the effect of the safflower on blood vessels finds that: for example, the blood vessel is perfused by Rockwell fluid containing trace adrenaline or noradrenaline, so that the smooth muscle of the isolated blood vessel of the animal is contracted to keep certain blood vessel tension, and the blood vessel obstruction and blood stasis state which may be similar to that of people are caused. Safflower can make the hind limb and rabbit ear of guinea pig with increased tension show vasodilatation, and has obvious effect with increasing dosage, and safflower can also increase blood flow of anesthetic dog femoral artery, but can contract normal isolated blood vessel of toad and rabbit. The safflower vasodilatation effect is related to the functional state of blood vessels and the dosage of the medicine. The mechanism of action may be mainly vasodilatation, directly or partially against the action of alpha-adrenergic receptors, with weaker direct vasoconstrictive action.
5. Influence of safflower on cerebral edema caused by ischemic stroke of experimental animals: applying a safflower injection (1ml contains 1g of crude drug), performing preoperative 30 minutes for 63 Mongolian gerbils and ip administering to 10g/kg of the safflower injection, establishing an operation control group and a pseudo-operation group, observing the influence of safflower on ischemic cerebral edema, and researching the change of the content of monoamine neurone in the same brain area. The results suggest that the mechanism by which safflower relieves ischemic cerebral edema may be associated with metabolic disorders that affect monoamine neurotransmitters in tissues. Further proves that safflower can actually reduce the incidence rate and the death rate of cerebral apoplexy and has a protective effect on the brain tissue of experimental animals with the thoracic infarction.
6. The function of reducing blood pressure: the safflower decoction, safflower yellow and other preparations have different degrees of rapid blood pressure reduction effects on anesthetized cats or dogs, the average blood pressure is reduced by about 20 mm Hg, and the recovery is realized after about 30 minutes.
7. Relieving pain and tranquilizing.
8. Has anti-inflammatory effect.
The efficacy of myrobalan:
myrobalan has the effects of relieving diarrhea with astringents, astringing lung to relieve cough, reducing pathogenic fire and relieving sore throat. It is commonly used for chronic diarrhea and dysentery, hematochezia and rectocele, cough and dyspnea due to lung deficiency, chronic cough, pharyngalgia and hoarseness.
The myrobalan has strong detoxification efficacy, not only can remove endogenous toxicosis caused by pathogenic qi gathering in the chest of a zang and zhuang chest, but also can remove exogenous toxicosis caused by food poisoning drugs, snake bite and the like. The water decoction of myrobalan has strong gonococcus resisting effect in vitro. The alcohol extract of fructus Chebulae has the effect of enhancing the contractile function and excitability of the atrial muscle. The myrobalan alcohol extract can shorten the effective refractory period of the left atrial muscle, reduce the maximum driving frequency of the left atrial muscle and improve the excitability of left atrial muscle cells.
The efficacy of gardenia:
fructus Gardeniae is also called as fructus Gardeniae, and Bufo bufo gargarizans, and has effects in protecting liver, promoting bile flow, lowering blood pressure, tranquilizing mind, stopping bleeding, and relieving swelling. Is used for treating icteric hepatitis, sprain, contusion, hypertension, diabetes and other diseases in traditional Chinese medicine clinic. The gardenia yellow wine has the health-care function, is a natural plant pigment integrating the functions of coloring, nutrition and health care, has the functions of clearing heat, removing fire, cooling blood, benefiting gallbladder and reducing cholesterol, and has certain health-care function.
The efficacy of licorice is:
licorice root, radix Glycyrrhizae has the main functions of clearing away heat and toxic material, expelling phlegm and arresting cough, and alleviating epigastric pain and abdominal pain.
1. Acid resistance: licorice root has the similar effect of adrenocortical hormone. Has inhibitory effect on hyperacidity caused by histamine; it also has antacid and spasmodic effects on smooth muscle of stomach and intestine.
2. Relieving cough: licoflavone, glycyrrhiza extract and glycyrrhetinic acid have obvious cough relieving effect; the phlegm eliminating effect is also obvious, and the action strength is glycyrrhizic acid, licoflavone and liquorice extract.
3. Anti-inflammatory and anti-allergic: the Glycyrrhrizae radix has antiinflammatory and antiallergic effects, and can protect inflamed throat and trachea mucosa. The glycyrrhiza extract and glycyrrhizic acid have detoxifying effect similar to that of glucuronic acid on certain toxicants.
4. Balancing hormones in women: licorice is commonly used for treating symptoms accompanying menopause because it contains liquiritigenin, a hormone-like compound that helps to balance the hormone content in women.
5. And (3) tumor prevention and treatment: the hypochlorous acid contained in Glycyrrhrizae radix can block carcinogen from inducing tumor growth.
The invention provides an extraction method of ellagic acid and myrobalamin acid in myrobalan and a composition with the effects of clearing away heat and toxic materials, removing liver fire, improving eyesight, resisting inflammation, reducing blood pressure, reducing blood fat, tonifying heart, nourishing nerve cells, prolonging life and the like, and compared with the prior art, the medicine has the beneficial effects that:
1. through selecting proper extracting solution and refluxing conditions, the extraction pertinence of the ellagic acid and the myrobalan acid in the myrobalan is higher, and the purity is higher.
2. By selecting proper chromatographic column and eluent, the components of the extract are simple in type, and the extraction pertinence of the ellagic acid and the myrobalam acid in the myrobalam is stronger.
3. The reasonable compatibility of the traditional Chinese medicine components ensures that the product has good effects of reducing blood pressure and blood fat, and also has remarkable effects of diminishing inflammation and improving eyesight.
4. By determining the mass ratio of the safflower to the liquorice, the myrobalan to the gardenia, the effects of the product on reducing blood pressure and blood fat, diminishing inflammation and improving eyesight are effectively improved.
Detailed Description
The invention will be further described with reference to specific embodiments, the advantages and features of which will become apparent from the description, but which are given by way of illustration only and are not intended to limit the scope of the invention in any way. It will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention, and that such changes and modifications may be made without departing from the spirit and scope of the invention.
Example 1
The extraction method of ellagic acid and myrobalamin acid comprises the following steps:
(1) pretreatment: pulverizing fructus Chebulae, and sieving with 200 mesh sieve;
(2) extraction 1: and (2) performing reflux extraction on the crushed myrobalan, wherein a solvent used for the reflux extraction is a methanol-ethanol-water solution, wherein the ratio of methanol: ethanol: water 5: 5:1, solvent: myrobalan-8: 1, then passing through a microporous filter membrane to obtain a solid A and an extracting solution A; the reflux extraction conditions were: the reflux temperature is 45 ℃; the reflux time is 1h
(3) And (3) extraction 2: and performing reflux extraction on the solid A, wherein a solvent used in the reflux extraction is an acetic acid-water solution, wherein the ratio of acetic acid: water 2:1, solvent: myrobalan-5: 1, then passing through a microporous filter membrane to obtain a solid B and an extracting solution B; the reflux extraction conditions were: the reflux temperature is 80 ℃; the reflux time was 1 h.
(4) Separation: mixing the extract A and the extract B, concentrating, passing through HPD-100 macroporous adsorbent resin, eluting with 83.3% ethanol-water solvent, and dissolving: (extract a + extract B) ═ 5:1, crystallizing and drying to obtain the ellagic acid and the chebulagic acid in the chebula fruit.
Preparation of the composition:
5 parts of safflower, 5 parts of myrobalan, 2 parts of gardenia, 5 parts of liquorice, and 0.02 part of ellagic acid and myrobalan acid in the myrobalan.
Mixing all the components, pulverizing, sieving with 60 mesh sieve, and sterilizing to obtain the composition.
Example 2
The extraction method of ellagic acid and myrobalamin acid comprises the following steps:
(1) pretreatment: pulverizing fructus Chebulae, and sieving with 300 mesh sieve;
(2) extraction 1: and (2) performing reflux extraction on the crushed myrobalan, wherein a solvent used for the reflux extraction is a methanol-ethanol-water solution, wherein the ratio of methanol: ethanol: water 5: 10:1, solvent: myrobalan 12: 1, then passing through a microporous filter membrane to obtain a solid A and an extracting solution A; the reflux extraction conditions were: the reflux temperature was 65 ℃; the reflux time is 3h
(3) And (3) extraction 2: and performing reflux extraction on the solid A, wherein a solvent used in the reflux extraction is an acetic acid-water solution, wherein the ratio of acetic acid: water 5:1, solvent: myrobalan-10: 1, then passing through a microporous filter membrane to obtain a solid B and an extracting solution B; the reflux extraction conditions were: the reflux temperature was 65 ℃; the reflux time was 3 h.
(4) Separation: mixing the extract A and the extract B, concentrating, passing through SD-300 macroporous adsorbent resin, eluting with 88.9% ethanol-water solvent, and dissolving: (extract a + extract B) ═ 11: 1, crystallizing and drying to obtain the ellagic acid and the myrobalan acid in the myrobalan.
Preparation of the composition:
the composition comprises 15 parts of safflower, 15 parts of myrobalan, 10 parts of gardenia, 8 parts of liquorice, and 0.03 part of ellagic acid and myrobalan acid in the myrobalan.
Mixing all the components, pulverizing, sieving with 80 mesh sieve, and sterilizing to obtain the composition.
Example 3
The extraction method of ellagic acid and myrobalamin acid comprises the following steps:
(1) pretreatment: pulverizing fructus Chebulae, and sieving with 250 mesh sieve;
(2) extraction 1: and (2) performing reflux extraction on the crushed myrobalan, wherein a solvent used for the reflux extraction is a methanol-ethanol-water solution, wherein the ratio of methanol: ethanol: water 5: 8: 1, solvent: myrobalan-10: 1, then passing through a microporous filter membrane to obtain a solid A and an extracting solution A; the reflux extraction conditions were: the reflux temperature is 50 ℃; the reflux time is 2h
(3) And (3) extraction 2: and performing reflux extraction on the solid A, wherein a solvent used in the reflux extraction is an acetic acid-water solution, wherein the ratio of acetic acid: water 3:1, solvent: myrobalan-8: 1, then passing through a microporous filter membrane to obtain a solid B and an extracting solution B; the reflux extraction conditions were: the reflux temperature is 70 ℃; the reflux time was 2 h.
(4) Separation: mixing the extract A and the extract B, concentrating, passing through D-101 macroporous adsorption resin, eluting with 66.7% methanol-water solvent, and dissolving: (extract a + extract B) ═ 8: 1, crystallizing and drying to obtain the ellagic acid and the myrobalan acid in the myrobalan.
Preparation of the composition:
9 parts of safflower, 10 parts of myrobalan, 5 parts of gardenia, 3 parts of liquorice, and 0.01 part of ellagic acid and myrobalan acid in the myrobalan.
Mixing all the components, pulverizing, sieving with 70 mesh sieve, and sterilizing to obtain the composition.
Example 4
The extraction method of ellagic acid and myrobalamin acid comprises the following steps:
(1) pretreatment: pulverizing fructus Chebulae, and sieving with 300 mesh sieve;
(2) extraction 1: and (2) performing reflux extraction on the crushed myrobalan, wherein a solvent used for the reflux extraction is a methanol-ethanol-water solution, wherein the ratio of methanol: ethanol: water 5: 7: 1, solvent: myrobalan ═ 9: 1, then passing through a microporous filter membrane to obtain a solid A and an extracting solution A; the reflux extraction conditions were: the reflux temperature was 55 ℃; the reflux time is 1.5h
(3) And (3) extraction 2: and performing reflux extraction on the solid A, wherein a solvent used in the reflux extraction is an acetic acid-water solution, wherein the ratio of acetic acid: water-4: 1, solvent: myrobalan ═ 7: 1, then passing through a microporous filter membrane to obtain a solid B and an extracting solution B; the reflux extraction conditions were: the reflux temperature is 75 ℃; the reflux time was 2.5 h.
(4) Separation: mixing the extract A and the extract B, concentrating, passing through D-101 macroporous adsorption resin, eluting with 66.7% methanol-water solvent, and dissolving: (extract a + extract B) ═ 10:1, crystallizing and drying to obtain the ellagic acid and the myrobalan acid in the myrobalan.
Preparation of the composition:
safflower 5 parts, myrobalan 5 parts, gardenia 1 part, liquorice 1 part, ellagic acid in myrobalan and myrobalan acid 0.01 part.
Mixing all the components, pulverizing, sieving with 70 mesh sieve, and sterilizing to obtain the composition.
Comparative example 1
Compared with the example 3, the composition is different and the compatibility is different.
48 parts of radix sophorae flavescentis, 22 parts of radix puerariae, 22 parts of acanthopanax, 32 parts of polygonum multiflorum, 32 parts of tribulus terrestris, 38 parts of gynostemma pentaphylla, 68 parts of rhizoma anemarrhenae, 20 parts of safflower, 16 parts of semen cassiae, 32 parts of scutellaria baicalensis, 15 parts of trichosanthes kirilowii maxim, 16 parts of caulis spatholobi, 11 parts of polygala tenuifolia, 32 parts of rhizoma atractylodis macrocephalae, 15 parts of seaweed, 32 parts of fructus gardeniae, 22 parts of pipewort, 38 parts of liquorice, 38 parts of cistanche and 32 parts of semen cuscutae.
Mixing all the components, pulverizing, sieving with 70 mesh sieve, and sterilizing to obtain the composition.
Comparative example 2
Compared with example 3, safflower and licorice have different contents, but the weight ratio is the same.
18 parts of safflower, 10 parts of myrobalan, 5 parts of gardenia and 6 parts of liquorice.
Mixing all the components, pulverizing, sieving with 70 mesh sieve, and sterilizing to obtain the composition.
Comparative example 3
Compared with the embodiment 3, the content and the proportion of each component are different.
Safflower 2 parts, myrobalan 4 parts, gardenia 12 parts, liquorice 9 parts, and ellagic acid and myrobalan acid 0.06 parts in myrobalan.
Mixing all the components, pulverizing, sieving with 70 mesh sieve, and sterilizing to obtain the composition.
Comparative example 4
Compared with example 3, the extraction process, i.e. steps (2-3), of the extraction method of ellagic acid and myrobalamin acid is different.
Wherein (2) extracting 1: and (2) performing reflux extraction on the crushed myrobalan, wherein a solvent used for the reflux extraction is an ethanol-water solution, wherein the ethanol: water-8: 1, solvent: myrobalan-10: 1, then passing through a microporous filter membrane to obtain a solid A and an extracting solution A; the reflux extraction conditions were: the reflux temperature is 75 ℃; the reflux time is 1h
(3) And (3) extraction 2: and performing reflux extraction on the solid A, wherein a solvent used in the reflux extraction is a methanol-water solution, wherein the ratio of methanol: water 3:1, solvent: myrobalan-8: 1, then passing through a microporous filter membrane to obtain a solid B and an extracting solution B; the reflux extraction conditions were: the reflux temperature is 4 ℃; the reflux time was 2 h.
Comparative example 5
Compared with example 3, the process for extracting ellagic acid and myrobalamin acid differs in the separation process, i.e. step (4).
Wherein, (4) separating: mixing the extract A and the extract B, concentrating, eluting with 80% ethanol-water solvent through DM130 macroporous adsorbent resin, and dissolving: (extract a + extract B) ═ 4: 1, crystallizing and drying to obtain the ellagic acid and the myrobalan acid in the myrobalan.
Effect example 1 measurement of content
The content of ellagic acid and chebulagic acid is determined by high performance liquid chromatography. Column C18(4.6 mm. times.250 mm, 5 μm); the mobile phase is methanol-water with the volume fraction of 50 percent; the flow rate was 1 mL/min.
The test results are given in the following table:
| group of | Example 1 | Example 2 | Example 3 | Example 4 | Comparative example 4 | Comparative example 5 |
| Ellagic acid purity | 52.3％ | 51.6％ | 53.1％ | 52.7％ | 36.8％ | 40.1％ |
| Purity of chebulac acid | 45.3％ | 44.6％ | 45.6％ | 44.9％ | 32.6％ | 36.4％ |
Effect example 2 lipid-lowering Effect
Taking 80 male SD rats with weight of 150 + -10 g, randomly dividing into 8 groups, each group containing 10 rats, and feeding high fat feed until the end of administration, wherein 4 groups are tea beverages prepared from the composition prepared in examples 1-4 by starting gavage simultaneously with feeding high fat feed, and are respectively named as examples 1-4 groups; 3 groups of tea beverages prepared from the compositions prepared in comparative examples 1 to 3, which were administered with high-fat diet and started to be gavaged, were named as comparative examples 1 to 3, respectively; the group 1 was fed with high-fat diet and started to be infused with gastric water, which was called high-fat group; the gavage volume was 1mL/10g by weight, and each group was administered for 30 days.
Tea beverages made with the compositions prepared in examples 1-4 and tea beverages made with the compositions prepared in comparative examples 1-3 were prepared by the following methods: 10g of the composition is taken, 100ml of water with the temperature of 80 ℃ is added, the mixture is soaked for 10min, and the mixture is cooled to the room temperature.
The high-fat feed comprises the following components: 80% of basal feed, 10% of lard oil, 9.5% of egg yolk powder and 0.5% of pig bile salt.
After fasting for 24h on the last day of administration, the femoral artery of the rat was bled, and serum was centrifuged to measure TC (total cholesterol), TG (triglyceride), HDL-C (high density lipoprotein cholesterol), and the experimental results are shown in the following table.
Note: p <0.05 between different letters for the same test item.
Effect example 3 antihypertensive Effect
70 spontaneous hypertensive rats weighing 150 + -10 g were randomly divided into 7 groups of 10 animals each, and 4 groups of the animals were fed with the diet and the tea beverages prepared from the compositions prepared in examples 1-4 were administered to the animals, and the animals were referred to as examples 1-4; 3 groups of tea beverages prepared from the compositions prepared in comparative examples 1 to 3, which were started to be gavaged while feeding the feed, were referred to as comparative examples 1 to 3, respectively; another 10 normal rats served as a control group and were fed with the diet while the gavage was started. The gavage volume was measured as 1.0mL/10g body weight for 30 consecutive days.
Tea beverages made with the compositions prepared in examples 1-4 and tea beverages made with the compositions prepared in comparative examples 1-3 were prepared by the following methods: 10g of the composition is taken, 100ml of water with the temperature of 80 ℃ is added, the mixture is soaked for 10min, and the mixture is cooled to the room temperature.
After the animals are adaptively raised for one week, the systolic pressure and the diastolic pressure of each group of animals are respectively detected by a non-invasive tail artery blood pressure meter. After the intragastric administration is finished, the indexes are detected again. The results of the experiment are shown in the following table:
note: p <0.05 between different letters for the same test item.
Effect example 4 anti-inflammatory Effect
The detection of CRP is widely used to monitor different inflammatory states and also to monitor the effect of treatment on inflammation.
Taking 70 rats with inflammation, weighing 150 + -10 g, randomly dividing into 7 groups, each group containing 10 rats, wherein 4 groups begin to gaze the tea beverage prepared from the composition prepared in examples 1-4 while feeding the feed, and are respectively referred to as examples 1-4; 3 groups of tea beverages prepared from the compositions prepared in comparative examples 1 to 3, which were started to be gavaged while feeding the feed, were referred to as comparative examples 1 to 3, respectively; another 10 normal rats served as a control group and were fed with the diet while the gavage was started. The gavage volume was measured as 1.0mL/10g body weight for 30 consecutive days.
Tea beverages made with the compositions prepared in examples 1-4 and tea beverages made with the compositions prepared in comparative examples 1-3 were prepared by the following methods: 10g of the composition is taken, 100ml of water with the temperature of 80 ℃ is added, the mixture is soaked for 10min, and the mixture is cooled to the room temperature.
After the animals are adaptively raised for one week, the femoral artery of the rat is subjected to blood taking, serum is centrifugally taken to measure the content of CRP in the serum, after the last day of administration is fasted for 24 hours, the femoral artery of the rat is subjected to blood taking, and serum is centrifugally taken to measure the content of CRP in the serum. The results of the experiment are shown in the following table:
| group of | CRP (mg/L) after feeding for one week | CRP (mg/L) after administration |
| Control group | 8.6±1.2a | 7.2±2.1c |
| Example 1 | 21.4±1.6a | 12.1±1.4b |
| Example 2 | 22.6±1.5a | 10.3±1.5b |
| Example 3 | 20.9±1.7a | 9.8±2.2b |
| Example 4 | 21.8±2.1a | 8.5±1.7b |
| Comparative example 1 | 22.1±1.9a | 20.3±1.8b |
| Comparative example 2 | 20.5±2.2a | 16.6±1.4b |
| Comparative example 3 | 21.8±1.9a | 14.8±2.1b |
Note: p <0.05 between different letters.
The comprehensive test result shows that the method has the following advantages:
1. through selecting proper extracting solution and refluxing conditions, the extraction of the ellagic acid and the myrobalan acid in the myrobalan is stronger in pertinence and higher in purity.
2. By selecting proper chromatographic columns and eluent, the components of the extract are simple in type, and the extraction pertinence of the ellagic acid and the myrobalan acid in the myrobalan is stronger.
3. The reasonable compatibility of the traditional Chinese medicine components ensures that the product has good effects of diminishing inflammation, reducing blood pressure and blood fat, and also has obvious effect on improving eyesight.
4. By determining the mass ratio of the safflower to the liquorice, the myrobalan to the gardenia, the effects of the product on reducing blood pressure and blood fat, diminishing inflammation and improving eyesight are effectively improved.
The technical means disclosed by the scheme of the invention are not limited to the technical means disclosed above, and the technical means also comprises the technical scheme formed by any combination of the technical features. While the foregoing is directed to embodiments of the present invention, it is noted that various changes and modifications may be made by one skilled in the art without departing from the spirit and scope of the invention.
Claims (4)
1. The composition for reducing blood pressure and blood fat, diminishing inflammation and improving eyesight is characterized by comprising the following components in parts by weight: 5-15 parts of safflower, 5-15 parts of myrobalan, 1-10 parts of gardenia, 1-8 parts of liquorice and 0.01-0.03 part of ellagic acid and myrobalan acid in the myrobalan;
wherein, the safflower comprises the following components in parts by weight: 1, myrobalan: 1 is cape jasmine (1-3);
the extraction method of the ellagic acid and the myrobalan acid in the myrobalan is characterized by comprising the following steps of:
(1) pretreatment: pulverizing fructus Chebulae, and sieving;
(2) extraction 1: extracting pulverized fructus Chebulae under reflux, and filtering with microporous membrane to obtain solid A and extractive solution A;
(3) and (3) extraction 2: carrying out reflux extraction on the solid A, and then passing through a microporous filter membrane to obtain a solid B and an extracting solution B;
(4) separation: mixing the extract A and the extract B, concentrating, passing through macroporous adsorption resin, eluting with solvent, crystallizing, and drying to obtain ellagic acid and myrobalamin acid in fructus Chebulae;
in the step (2), the solvent used for reflux extraction is methanol-ethanol-water solution; the solvent comprises the following components in parts by weight: myrobalan (8-12): 1, methanol: ethanol: water 5: (5-10): 1; the reflux temperature is 45-65 ℃; the reflux time is 1-3 h;
in the step (3), the solvent used for reflux extraction is acetic acid-water solution; the solvent comprises the following components in parts by weight: myrobalan ═ 5-10: 1, acetic acid: water ═ 2-5: 1; the reflux extraction conditions were: the reflux temperature is 65-80 ℃; the reflux time is 1-3 h;
in the step (4), the type of the macroporous adsorption resin is one of HPD-100, D-101 or SD-300.
2. The composition as claimed in claim 1, wherein in step (1), the pulverization is sieved through 200-300 mesh.
3. The composition of claim 1, wherein in step (4), the solvent is one of ethanol-water or methanol-water; the solvent comprises the following components in parts by weight: (extract a + extract B) ═ 5-11): 1.
4. a process for the preparation of a composition according to any one of claims 1 to 3, characterized in that it comprises the following steps: mixing all the components, pulverizing, sieving, and sterilizing to obtain the composition.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910357486.7A CN109966328B (en) | 2019-04-29 | 2019-04-29 | Method for extracting ellagic acid and myrobalan acid from myrobalan and composition thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910357486.7A CN109966328B (en) | 2019-04-29 | 2019-04-29 | Method for extracting ellagic acid and myrobalan acid from myrobalan and composition thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109966328A CN109966328A (en) | 2019-07-05 |
| CN109966328B true CN109966328B (en) | 2022-05-10 |
Family
ID=67087027
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910357486.7A Active CN109966328B (en) | 2019-04-29 | 2019-04-29 | Method for extracting ellagic acid and myrobalan acid from myrobalan and composition thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109966328B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111514151B (en) * | 2020-05-09 | 2022-08-09 | 中国科学院昆明植物研究所 | Application of three compounds in myrobalan in preparing anti-inflammatory drugs and preparation method thereof |
| CN114414701B (en) * | 2022-01-28 | 2023-06-13 | 辽宁中医药大学 | Preparation method of myrobalan acid in myrobalan meat and content determination method thereof |
| CN117323326A (en) * | 2023-11-20 | 2024-01-02 | 四川大学华西医院 | Application of urolithin A in preparation of medicine for preventing and treating severe acute pancreatitis related cardiac injury |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101433563A (en) * | 2007-11-13 | 2009-05-20 | 天津天士力制药股份有限公司 | Effective component of chebula fruit as well as preparation method and use thereof |
| CN105949252A (en) * | 2016-01-29 | 2016-09-21 | 中国科学院西北高原生物研究所 | Preparation method of three chemical reference substances chebulinic acid, chebuligic acid and ellagic acid in terminalia chebula medicine |
| CN109453212A (en) * | 2019-01-06 | 2019-03-12 | 北京中医药大学 | A kind of Fructus Terminaliae Billericae extract and its active component preparation method with antitumaous effect |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1073358C (en) * | 1997-11-26 | 2001-10-24 | 马进忠 | Youthfulness buc tea |
| CN1883671A (en) * | 2006-05-27 | 2006-12-27 | 端智 | Liver-benefiting blood circulation-activating eyesight-improving granule |
| CN1883670A (en) * | 2006-05-27 | 2006-12-27 | 端智 | Liver-benefiting blood circulation-activating eyesight-improving tablet |
| CN101912009A (en) * | 2010-08-24 | 2010-12-15 | 叶宗菊 | Health protection tea |
| CN102008591B (en) * | 2010-12-10 | 2012-07-25 | 冯学安 | Traditional Chinese medicine capsule for treating hypertension |
| CN104664369B (en) * | 2015-01-14 | 2016-08-24 | 厦门医学高等专科学校 | A kind of Radix et Rhizoma Gynurae divaricatae health food of blood pressure lowering uric acid resisting and preparation method thereof |
-
2019
- 2019-04-29 CN CN201910357486.7A patent/CN109966328B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101433563A (en) * | 2007-11-13 | 2009-05-20 | 天津天士力制药股份有限公司 | Effective component of chebula fruit as well as preparation method and use thereof |
| CN105949252A (en) * | 2016-01-29 | 2016-09-21 | 中国科学院西北高原生物研究所 | Preparation method of three chemical reference substances chebulinic acid, chebuligic acid and ellagic acid in terminalia chebula medicine |
| CN109453212A (en) * | 2019-01-06 | 2019-03-12 | 北京中医药大学 | A kind of Fructus Terminaliae Billericae extract and its active component preparation method with antitumaous effect |
Non-Patent Citations (1)
| Title |
|---|
| 诃子抑菌活性成分筛选和总鞣质含量测定新方法;何淼等;《基因组学与应用生物学》;20171231;第36卷(第12期);5167-5172 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109966328A (en) | 2019-07-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103285231B (en) | Medicine composition for diabetes adjunctive therapy and preparation method thereof | |
| CN109966328B (en) | Method for extracting ellagic acid and myrobalan acid from myrobalan and composition thereof | |
| CN102380051B (en) | Medicinal steamed bread for treating diabetes | |
| CN106975012B (en) | Traditional Chinese medicine composition for reducing blood sugar and preparation method thereof | |
| CN101239112A (en) | Traditional Chinese medicine composition for regulating blood lipid and preparation method thereof | |
| CN108524814A (en) | A kind of Chinese medicine composition and preparation method thereof for reducing blood glucose | |
| CN113616709A (en) | A kind of traditional Chinese medicine composition for treating male infertility and preparation process thereof | |
| CN104173451B (en) | The application in blood sugar lowering medicine and health food of a kind of natural drug composition | |
| CN103933346A (en) | Blood-glucose-reducing composition and preparation method thereof | |
| CN103705594A (en) | Traditional Chinese medicine composition for treating hyperlipidemia and preparation method thereof | |
| CN104815166A (en) | Traditional Chinese medicine composition for treating diabetes as well as preparation and application of traditional Chinese medicine composition | |
| CN103655791A (en) | Lotus leaf-based preparation for treating phlegm and blood stasis simultaneously and application thereof | |
| CN101664541B (en) | Medicament for treating dysmenorrhoea and preparation method thereof | |
| CN106109521A (en) | A kind of Radix Notoginseng oral liquid | |
| CN107773679A (en) | A kind of composition and its preparation technology for aiding in reducing blood lipid, aiding in thrombus | |
| CN103083429B (en) | Blood fat-reducing traditional Chinese medicine formula | |
| CN113144117A (en) | Traditional Chinese medicine composition for treating diabetes and preparation method and application thereof | |
| CN100534502C (en) | Asparagus extract and preparation method thereof | |
| CN112402569A (en) | Anti-fatigue health product and preparation method thereof | |
| CN1150839C (en) | Health food with blood pressure and blood lipoid regulating function and its production process | |
| CN106420932B (en) | A composition for increasing insulin sensitivity and application thereof | |
| CN111569012B (en) | Traditional Chinese medicine composition for treating sepsis myocardial injury and preparation method thereof | |
| CN114796417B (en) | Blood sugar reducing traditional Chinese medicine formula and preparation method thereof | |
| CN114848764B (en) | Traditional Chinese medicine compound composition for preventing and treating liver injury and preparation method and application thereof | |
| CN103099886A (en) | Soft capsule helpful for improving intestinal and gastric functions and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20220325 Address after: 028011 north of turjishan street and east of Kulun Road, Tongliao Economic and Technological Development Zone, Inner Mongolia Autonomous Region (in the hospital of Inner Mongolia keriqin Mongolian Medical Instrument Co., Ltd.) Applicant after: Inner Mongolia Arshan Pharmaceutical Co.,Ltd. Address before: 029300 Tongliao Kezuo Middle Banner Mongolian Medical Hospital, Inner Mongolia Autonomous Region Applicant before: Bai Jirimutu |
|
| TA01 | Transfer of patent application right | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |